Tonghua Dongbao Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 1.96%

Tonghua Dongbao Pharmaceutical Co Ltd (600867) has an Asset Resilience Ratio of 1.96% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Tonghua Dongbao Pharmaceutical Co Ltd total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥160.00 Million
≈ $23.41 Million USD Cash + Short-term Investments

Total Assets

CN¥8.15 Billion
≈ $1.19 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Tonghua Dongbao Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 600867 total equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Tonghua Dongbao Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 600867 company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥160.00 Million 1.96%
Total Liquid Assets CN¥160.00 Million 1.96%

Asset Resilience Insights

  • Limited Liquidity: Tonghua Dongbao Pharmaceutical Co Ltd maintains only 1.96% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Tonghua Dongbao Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Tonghua Dongbao Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
Drug Manufacturers - Specialty & Generic 0.44%
Emcure Pharmaceuticals Ltd
NSE:EMCURE
Drug Manufacturers - Specialty & Generic 1.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Ningbo Menovo Pharm Co Ltd
SHG:603538
Drug Manufacturers - Specialty & Generic 2.69%
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
Drug Manufacturers - Specialty & Generic 20.24%
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
Drug Manufacturers - Specialty & Generic 0.40%

Annual Asset Resilience Ratio for Tonghua Dongbao Pharmaceutical Co Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Tonghua Dongbao Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.75% CN¥55.40 Million
≈ $8.11 Million
CN¥7.38 Billion
≈ $1.08 Billion
+0.04pp
2023-12-31 0.71% CN¥55.52 Million
≈ $8.12 Million
CN¥7.77 Billion
≈ $1.14 Billion
-0.15pp
2022-12-31 0.87% CN¥58.46 Million
≈ $8.55 Million
CN¥6.75 Billion
≈ $987.78 Million
+0.30pp
2021-12-31 0.57% CN¥37.00 Million
≈ $5.41 Million
CN¥6.52 Billion
≈ $954.10 Million
-2.02pp
2020-12-31 2.59% CN¥150.37 Million
≈ $22.00 Million
CN¥5.80 Billion
≈ $849.20 Million
-3.32pp
2018-12-31 5.91% CN¥323.00 Million
≈ $47.27 Million
CN¥5.46 Billion
≈ $799.46 Million
-0.65pp
2017-12-31 6.56% CN¥312.00 Million
≈ $45.66 Million
CN¥4.75 Billion
≈ $695.47 Million
-1.99pp
2016-12-31 8.56% CN¥400.00 Million
≈ $58.53 Million
CN¥4.68 Billion
≈ $684.10 Million
--
pp = percentage points

About Tonghua Dongbao Pharmaceutical Co Ltd

SHG:600867 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.67 Billion
CN¥18.23 Billion CNY
Market Cap Rank
#5351 Global
#1076 in China
Share Price
CN¥9.31
Change (1 day)
+0.87%
52-Week Range
CN¥7.40 - CN¥10.49
All Time High
CN¥23.57
About

Tonghua Dongbao Pharmaceutical Co., Ltd. researches, develops, produces, and markets pharmaceuticals in China. It offers human insulin injections; insulin glargine injections; insulin aspart injections; liraglutide injections; and proprietary Chinese medicine. The company also provides insulin pen and pen needles; and chronic disease management platform, a diabetes management platform for drug tr… Read more